Early treatment of endometriosis with GnRH-agonists: Impact on time to recurrence

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 93, Issue 2, 2000, Pages 123-125

  Schindler, Adolf E ^a   Foertig, Peter ^b   Kienle, Erika ^b   Regidor, Pedro A ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

Endometriosis; Follow up; GnRH agonist; Recurrence rate

Indexed keywords

GONADORELIN AGONIST;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT INDICATION;

EID: 0033768591     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00244-X     Document Type: Article

References (5)

1. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: Long-term follow-up
2. Changing trends in the diagnosis of endometriosis: A comparative study of women with chronic pelvic pain or infertility
3. Ergebnisse eines Langzeit Follow-up bei der Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat-Depot (Enantone® -Gyn Monats-Depot)
4. Antigonadotropin (danazol) in the treatment of endometriosis: Evaluation of post-treatment fertility and three-year follow-up data
5. Endometriosis the case for early, aggressive treatment